No Rating Available
(Learn About Our Rating System)

Parisa Adelhardt, MD, MSc

Languages spoken: English

Board Certification

American Board of Pathology (Anatomic & Clinical) American Board of Pathology (Sub: Molecular Genetic Pathology)

Academic Departments	Pathology -Associate Professor (Clinical)
Board Certification	American Board of Pathology (Anatomic & Clinical) American Board of Pathology (Sub: Molecular Genetic Pathology)

Professional Medical	Medicine - Tehran University of Medical Sciences School of Medicine	M.D.
Graduate Training	Experimental Medicine - McGill University	M.Sc.
Residency	Anatomical and Clinical Pathology - University of New Mexico School of Medicine	Resident
Fellowship	Molecular Genetic Pathology - University of New Mexico School of Medicine	Fellow

Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Archives of pathology & laboratory medicine,
Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, Affolter K, Beech C, Jedrzkiewicz J, Ruano AL, Cleary AS, Mahlow J, Balatico M, Gulbahce H (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American journal of clinical pathology, 163(6), 837-846.
Beech C, Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim J, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2025). Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ Hybridization. Applied immunohistochemistry & molecular morphology, 33(2), 91-102.